SCHOTT Pharma AG & Co. KGaA (1SXP) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of SCHOTT Pharma AG & Co. KGaA stock €15.46, price €21.25, that is 27.2% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
37‑month range €12.96 – €40.40 · fair‑value band €8.61 – €20.23 · the €21.25 price screens above the €15.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow SCHOTT Pharma AG & Co. KGaA in your weekly email
Every Wednesday you see whether SCHOTT Pharma AG & Co. KGaA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide.
Show moreShow less
The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge.
It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials.
In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs.
Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules.
It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Stock analysis
SCHOTT Pharma AG & Co. KGaA (1SXP) currently trades at €21.25, while our model-based Fair Value estimate is €15.46, 27% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €21.32 per share, and 5 of the 26 models we run sit above the €21.25 price.
Bear case: the Dividend Discount group reads lowest at €2.74, and 21 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: €8.61 (bear) to €20.23 (bull), the price of €21.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SCHOTT Pharma AG & Co. KGaA reported revenue of €986M in FY2025 versus €649M in FY2021, a compound +11.0%/yr. Reported net income was €146M in FY2025, compounding +9.8%/yr from FY2021.
Key figures
Market cap €3.2B Mid · P/E ratio 23.6 · P/S ratio 3.51 · EPS (TTM) €0.9000 · Dividend yield 0.8% · Net margin 13.4% · Return on equity 14.7% · Return on assets (EBIT) 13.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −27%, 1SXP screens cheaper than that median.
Fair Value models
Bear€8.61Fair Value €15.46Bull€20.23
Price €21.25 · Downside -27.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (€0.7200 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+11.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.4%
Dividend (yield on the price)0.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 19%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+37.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +34.2% a year for the price and +3.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (23 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Operational progress in delivering expectations forms the main strength, but limited durable moat signals and thin public data represent the core weakness.
Main risk: The one-off payment this year risks producing modestly lower organic growth guidance for 2027 and would hit near-term expansion targets in pharma packaging.
Schott Pharma has made clear progress in delivering on expectations again. A one-off payment this year, however, could lead to modestly lower organic growth guidance for 2027 even while the medium-term outlook remains attractive. Our models see the shares as overvalued. Does operational momentum outweigh the risk of tempered near-term targets?
Compare SCHOTT Pharma AG & Co. KGaA with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Below median
Fair Value upside−27.2% · Below median
Profitability
Return on equity (12 months)14.7% · Top 25%
Return on assets9.2% · Top 25%
Net margin (12 months)13.4% · Above median
Operating margin (12 months)17.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.0% · Above median
Dividend yield (12 months)0.8% · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SCHOTT Pharma AG & Co. KGaA Fair Value". https://www.fairvalue-calculator.com/stock/1SXP
Frequently asked questions
Is SCHOTT Pharma AG & Co. KGaA (1SXP) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of €15.46 versus a price of €21.25, about 27% lower (overvalued).
What is the fair value of 1SXP?
Our model-based fair value for SCHOTT Pharma AG & Co. KGaA is €15.46 (as of Nov 10, 2026), built from audited fundamentals. The current price: €21.25.
What is the quality score of 1SXP?
SCHOTT Pharma AG & Co. KGaA has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SCHOTT Pharma AG & Co. KGaA (1SXP)?
Our model-based price target is the fair value of €15.46 (as of Nov 10, 2026) from 26 valuation models. Cautious scenario €8.61, optimistic scenario €20.23. It is a calculation from audited fundamentals, not an analyst target.
What is the SCHOTT Pharma AG & Co. KGaA stock forecast for 2026?
Our models put fair value at €15.46, about 27% lower versus a price of €21.25 (overvalued). Cautious scenario €8.61, optimistic scenario €20.23. The calculation is refreshed regularly with new filings.
What is the revenue of SCHOTT Pharma AG & Co. KGaA (1SXP)?
SCHOTT Pharma AG & Co. KGaA reported trailing-twelve-month revenue of about €1.0B (latest available figure, as of Nov 10, 2026).
Does SCHOTT Pharma AG & Co. KGaA pay a dividend?
SCHOTT Pharma AG & Co. KGaA currently shows a dividend yield of 0.85% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of SCHOTT Pharma AG & Co. KGaA (1SXP) and when is the ex-dividend date?
SCHOTT Pharma AG & Co. KGaA pays a dividend of €0.18 per share a year, a dividend yield of 0.8%. The last ex-dividend date was Feb 4, 2026. The payout ratio is 20.0% of earnings. Free cash flow covers the dividend 1.30 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into SCHOTT Pharma AG & Co. KGaA (1SXP)?
For today's price to be fair in a discounted-cash-flow model, SCHOTT Pharma AG & Co. KGaA would have to grow free cash flow by +37.1 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of 1SXP use?
Our models discount SCHOTT Pharma AG & Co. KGaA at 9.2 %: a base by market capitalisation (mid), damped by beta 0.87, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SCHOTT Pharma AG & Co. KGaA that is +37.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has SCHOTT Pharma AG & Co. KGaA (1SXP) delivered so far?
Over the past 5 years revenue at SCHOTT Pharma AG & Co. KGaA grew +11.0 % a year. The price currently implies free-cash-flow growth of +37.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SCHOTT Pharma AG & Co. KGaA (1SXP) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into SCHOTT Pharma AG & Co. KGaA (+37.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The free-cash-flow yield on the price is 1.10 %: that much free cash flow SCHOTT Pharma AG & Co. KGaA produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SCHOTT Pharma AG & Co. KGaA (1SXP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SCHOTT Pharma AG & Co. KGaA it is €15.46 per share (as of Nov 10, 2026), against a price of €21.25. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is SCHOTT Pharma AG & Co. KGaA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 1SXP trades above its calculated fair value: price €21.25, fair value €15.46, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1SXP?
No. The price is what the market pays today (€21.25); the fair value is what the company's own numbers justify (€15.46). For SCHOTT Pharma AG & Co. KGaA the two are €5.79 per share apart. That gap is exactly why we show both numbers side by side.
How much is SCHOTT Pharma AG & Co. KGaA worth?
The market values SCHOTT Pharma AG & Co. KGaA at about €3.2B (market capitalisation, as of Nov 10, 2026). Per share that is €21.25; our models calculate a fair value of €15.46 per share.
What do the bullish and bearish scenarios say about 1SXP?
Our models span a range for SCHOTT Pharma AG & Co. KGaA: cautious scenario €8.61, base €15.46, optimistic €20.23 per share (as of Nov 10, 2026, price €21.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1SXP?
SCHOTT Pharma AG & Co. KGaA trades at a price-to-earnings ratio of 23.6 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €15.46 is built from several models across several years. Other multiples: P/B 4.0, P/S 3.5, EV/EBITDA 14.2.
How solid is the balance sheet of SCHOTT Pharma AG & Co. KGaA (1SXP)?
Balance-sheet figures for SCHOTT Pharma AG & Co. KGaA (as of Nov 10, 2026): return on equity 14.7%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 1SXP from its 52-week high?
SCHOTT Pharma AG & Co. KGaA trades at €21.25, about 18% below its 52-week high of €26.00 and 64% above the low of €12.96 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €15.46 is for.
Which stocks are comparable to SCHOTT Pharma AG & Co. KGaA?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SCHOTT Pharma AG & Co. KGaA stock attractive at the current price?
The data as of Nov 10, 2026: price €21.25, calculated fair value €15.46 (−27%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1SXP calculated?
We run SCHOTT Pharma AG & Co. KGaA through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €15.46 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. SCHOTT Pharma AG & Co. KGaA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The closing price on Nov 9, 2026 was €21.25. Our model-based fair value is €15.46, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SCHOTT Pharma AG & Co. KGaA right now?
The price sits above even our optimistic bull case (€20.23). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€8.61 to €20.23) leaves room in how you read the outcome.
Key figures of SCHOTT Pharma AG & Co. KGaA
How large is the market capitalisation of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The market capitalisation of SCHOTT Pharma AG & Co. KGaA is €3.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The price-to-sales ratio of SCHOTT Pharma AG & Co. KGaA is 3.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SCHOTT Pharma AG & Co. KGaA (1SXP)?
Earnings per share at SCHOTT Pharma AG & Co. KGaA are €0.9000 (price ÷ EPS = P/E 23.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The dividend yield of SCHOTT Pharma AG & Co. KGaA is 0.8% (payout 20.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The net margin of SCHOTT Pharma AG & Co. KGaA is 13.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The return on equity (ROE) of SCHOTT Pharma AG & Co. KGaA is 14.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SCHOTT Pharma AG & Co. KGaA (1SXP)?
On an EBIT basis the return on assets of SCHOTT Pharma AG & Co. KGaA is 13.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SCHOTT Pharma AG & Co. KGaA (1SXP)?
The operating margin of SCHOTT Pharma AG & Co. KGaA is 17.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SCHOTT Pharma AG & Co. KGaA (1SXP)?
Revenue at SCHOTT Pharma AG & Co. KGaA is growing +10.0% versus a year earlier (3y avg +6.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SCHOTT Pharma AG & Co. KGaA (1SXP)?
Earnings per share at SCHOTT Pharma AG & Co. KGaA are growing −13.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch SCHOTT Pharma AG & Co. KGaA in the live analysis
One click puts SCHOTT Pharma AG & Co. KGaA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 10, 2026